Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.
The €8.7 million series B will support studies targeting two bacterial infections and the creation of a drug manufacturing unit.
The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.
Canadian biotech Adapsyn Bioscience has developed a system that could sift out promising drug candidates from microbes more quickly—catching the eye of a big…
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.
The financing will position Evolus to challenge Allergan’s grip on the wrinkle-busting sector by bringing a biosimilar copy of Botox to market.
Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.
Big Pharma Pfizer will cut around 300 jobs and a number of earlier stage projects from its neuroscience pipeline.